GALT – galectin therapeutics inc. (US:NASDAQ)
Stock Stats
News
Galectin Therapeutics: Runway With Convertible Financing But Dilution Overhang Remains [Seeking Alpha]
Galectin Therapeutics Receives FDA Written Response on Belapectin, Adds $10 Million Credit Line [Yahoo! Finance]
Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027 [Yahoo! Finance]
Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027
Galectin Therapeutics (NASDAQ:GALT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Form 4/A GALECTIN THERAPEUTICS For: Dec 23 Filed by: FREEMAN KEVIN D
Form 4/A GALECTIN THERAPEUTICS For: Dec 23 Filed by: FREEMAN KEVIN D
Form 4 GALECTIN THERAPEUTICS For: Dec 23 Filed by: ELDRED KARY
Form 4 GALECTIN THERAPEUTICS For: Dec 23 Filed by: FREEMAN KEVIN D
Form 4 GALECTIN THERAPEUTICS For: Dec 23 Filed by: ELDRED KARY
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.